Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202310039 A Phase I/IIa, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of UA002 (Allogeneic Amniotic Fluid Stem Cells) in Subjects with Diabetes Mellitus (DM)- or Radical Prostatectomy (RP)-Associated Erectile Dysfunction (ED) New Medical Technology NA
N202310052 A Phase III, Multicentre, Randomised, Double-blind, Chronic dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA) New Drug Phase Ⅲ
N202311007 A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator’s Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1) New Drug Phase Ⅲ
N202311008 A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5) New Drug Phase Ⅲ
N202311026 CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next- Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2-Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease New Drug Phase Ⅲ
N202311064 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study) New Drug Phase Ⅲ
N202311079 A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TRX-920 Oral Gel (10 mg and 30 mg) in Patients with Advanced Solid Tumors New Drug Phase Ⅰ
N202312002 A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy New Drug Phase Ⅲ
1 2 12 13 14 15 16 17 18 51 52 / 52

TOP